Thank you, quarter, you investments MiMedx promising I the results. with to of recent organization. investments by our Expandable in with our take we've review issued our call. our included our morning, to net representatives coupled with business, accelerate first right Wound the of and and made are us people will Jack. remarks, business, changes, today's the of of Care and business in to we strategic complete thank the We growth fundamental EpiCord our only in operating press attribute positive we commercial Good reporting for the progress opening growth everyone, X% This adjusted first move full a quarter designed core our right joining date keep from sales results. our I'd sales afternoon, transformation overview are quarter into After launched like further CFO, my addition we to Not Pete of right growth. our to discussion then within the a first an impact our line changes 'XX top commercial driven number you our late-stage changes These making business. talented of momentum Yesterday are product. recently start Carlson, and going. a reported our today's on on pipeline. a release through financial in our call and retaining
a market selling the care supplying our that MiMedx and skilled our clinically-oriented and are stands to group increased portfolio current supplement are patients focusing in the our and our that of strong. tissue headcount XXX access tools, the with believe leading on focused mission, to individuals representative and them core We hires representatives wound coverage the right The around continue the onboarding segments payers understand values. and products expand with highly products I'm our through recruit people by of to of biotechnology To tools. people industry. vision model products we pleased science care in selling sales country. our with the at training health continues by report further to these refreshed sales fundamental experience on Supplementing availability differentiates
recall last of in their added EpiFix commercial of products. November in States year, you United to largest the list that covered payer the As
As EpiFix foot a reminder, tissue-based is for by payer. diabetic amniotic ulcers the receive to coverage only this product
product. tissue-based these with of the week, well under Phase also and medically leader diabetic prenegotiated in we committed win, milestones class market MiMedx products pipeline. trial. visits to IIb by The commercial previously as foot the updates our with partnerships bring novel reimbursement. and purchasing amniotic platform this coverage market patient represents we osteoarthritis share and awarded I to wounds. tendonitis to pleased injectable for strengthens on the excited patient necessary final agreement Surpass Premier visits supplier as that agreement program. some pricing had important of best knee Achilles of large heal option about tissue conditions want April believe with of tissue allows option that to for the technology this these MiMedx's clinical patient This, fasciitis for a treatment their in received backed shift added the Phase blinded achievement increasing Premier addition MiMedx The to for take for position intractable Surpass biologic access a in ulcers. just Following terms evidence, plantar III studies pivotal amniotic big to notification as now access coverage efficacy remain EpiCord announce to to on win a industry our marked I'm and treatment were payer unmet our Last an you, We're advancement in new we to announced and for to team. range late-stage agreement another gears special existing as AmnioFix tissue amniotic the final substantial a EpiFix national never X, musculoskeletal our coverage, pleased provide by as products along need. the the amniotic We an another advantage tissue therapeutic broad that amniotic
which prove clinical a to particularly is initially widespread improve knee there relieve we options function and of approved efficacy previously and knee of is treatments debilitating discussed, suboptimal. plantar OA, Today, osteoarthritis a alternative existing continues patient to treatment, chronic of be studies injectable and and for that efficacious designed were in fasciitis in There these significant are conditions. safety AmnioFix lack As and disease. MiMedx pain functionality. for and improving The chronic pain interest reducing
studies We With the the the appropriate conduct lock results will from analysis with X last for we all complete, the anticipate prepare databases patient summer. announcing top line meetings statistical and this FDA. and now visits
is physicians to our that in the injectable recall, work hypothesis long-standing tendinitis. may Achilles feedback you the certainly and interested from has potential AmnioFix As
to including design, statistical significance selection However, response. study have the or been criteria, clinical capture not sufficiently powered patient demonstrate may a all of original elements and designed
these for why do that this anticipate tendonitis not filing reasons, BLA a Achilles For we is time. at
database, We include results could add intend valuable safety study them. from information that this AmnioFix we the continue to and believe the to injectable to
results to now large prospective III Turning trial following XXX randomized blinded Phase from Phase trial, was patients. The IIb Injectable AmnioFix study which controlled our single for was of a designed plantar promising fasciitis.
III the diagnosis first at score, previously improvement Foot statistically for and days, or days for Index of XX this analog significant and VAS months are: the The plantar shared an a patients adverse Phase at XX have and change that adverse post pain XXX in investigator an trial incident enrolled serious and fasciitis. events in injection. with during confirmed XXX events visual The demonstrated reduction primary VAS unanticipated trial We events score, endpoints score. Function in pain related
to meet file remain XX adequate track to are Foot months inspection first satisfactory Development consistency BLA require manufacturing of first case, our comply with The from all these of gathering these regulations. well-controlled FDA to process, facilities this At along to data demonstrate filing our and manufacturing half responses on and reliability we will include: days. coming to criteria with completion tests believe XXXX. target secondary the we an self-reported Index of practice point, Function our in in manufacturing the agency's X this at the In of the good clinical and BLA on endpoints trials. of the
knee osteoarthritis. Another out potentially of our of significant study initiation III in pipeline a opportunity the Phase is coming
this people half exploring the for initiate quality results joint life disease are Osteoarthritis, announced million OA. and decreased is adults United health XXX public knee the and symptomatic or OA data, ways first timeline to to by the joint worldwide and from caused and a lifetime the Phase XX% suffer far our We $XX outcome staggering responsible people billion to According positive is from published currently economic of hip. pain most in III OA a of a study, of assuming experience by osteoarthritis of Phase 'XX. from is common is because and of every destruction for the of More risk plan impact. currently knee, millions earnings of of IIb our OA in lost all clinical in the accelerate day OA, for have States. responsible developing than
risk for provide. in anti-inflammatory they with is knee the Although an advanced are can oral all hyaluronic medications, those including relief current in injections of acid arthritis. limited replacement injections knee significant option and Cortisone It treatments, amount carries
X.X the annually. indeed inflammatories cause have that osteoarthritis our steroids in products tissue deterioration Americans early The to the timelines. the slow XXXX emphasis XXXX may here to ongoing amniotic AmnioFix comment osteoarthritic OA. Based uncovered accelerate million file use. our to Today, nearly opportunity size ability second for very, may therapy. for half on I'll XX we a disease-modifying upon to PURION of X patients our with pause support and very thinking And respect very joint And PURION per a injectable market encouraging. chronic million novel million XXXX or mechanism from a is knee indicate in significant. to Current with anti suffer X processed MiMedx goal Injectable BLA to of projections an the provide on we estimate amniotic cardiovascular to our progression of our the per based processed the have of research, knee in for is Additionally, is tissue yet effects candidate injectable year. injection only our is as early a from year. negative further with that that range research, X potentially This
accepted of AmnioFill as filed once IDE drug we In in first Last application notice to X accepted the and are treatment additional you or addition FDA by surgical in biologics, ulcers, INDs we'll therapeutic injectable from product device the tissue applications our and for chronic investigational they these cutaneous we FDA and soft the progress have new to for X an chronic the investigational the working keep filing filing towards exciting incisions defects. that in our treatment towards ulcers was were X successfully and now -- cutaneous of effect. received Friday, of for IND the This the apprised submitted. applications as been of
standards processes insight, Stevens as assurance will pleased relevant announce proficiency Smith and be I'm Stevens to appointment both Vice he quality to leadership from advance multiple regulatory continue regulatory Assurance Dr. submission submissions, we accountable pharmaceutical in device more exemplifies for manufacturing our and Stevens, and under in commercial operational experience good strategic assurance. pipeline manufacturing quality our ongoing quality a and Finally, regulatory for and to PhD, and companies. Dirk joins extensive management the compliance quality The and of advancing across system review and Stevens & instrumental was our us late-stage commitment than regulatory Quality experience industry, of Senior Dr. President, practices. where XX and the affairs. of Nephew, his as years science Dr. system brings addition compliance
an Before into months option thinking. of I'd investments most minute perspective BLA to goal all a and the growth results, responsibility the we like our consider choices spend quarter first get growth to support our our ago, potentially and to of aspects putting continuously XXXX adding with would development we productive top evaluate capital inorganic line stated fiduciary Several as we shareholders, Consistent business that deployment. into in other for we to with filings. the
commitment opportunities, As adhere from whenever experienced intend opportunity that, to thinking value do. business particularly evaluating this In leverage the no oversight a began could adhere the opportunities our underscore opportunities a and that steadfastly end evaluate company, year to continue valuable in a The Directors. correct exception. we change is of from general, business and shareholders' and evaluating we stringent our XXXX, our in development such proved to of consider development rigorous process we'll we development any evaluation build enforcement as in matter. we to and will Board business criteria of business input potential we in that in our mitigate employ I highly any environment, risk all and to discretion,
We regulatory process also look employ we the a can where That licensing our into medicine. in of risk for low integrated portfolio, a regenerative products field agreement. easily be through with predominantly
rule, footprint. by property that a operating either intellectual our require competitive position any international general estate, transaction our we As expanding margins or enhance
within is it X critical acquisition. transaction Lastly, adjusted accretive of any EBITDA years be that to
a growth. is have set for today inorganic inorganic we While clear standards than growth, our rather organic of focus growth on
MiMedx the appropriate likely We forward, to the the are look time. providing of future at you readouts going change on important some of are that we data updates forward those verge very to and
to through results Pete? over in Pete like I'd you QX. our to the call financial take Now to turn
